PAREXEL’s Head of Learning and Development Named to 2015 PharmaVOICE 100 Most Inspiring People in the Life Sciences List
23 September 2015 - 11:00PM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, announced that
PharmaVOICE named Albert Siu, PhD, Vice President, Learning and
Development, PAREXEL, one of 2015’s PharmaVOICE 100 Most Inspiring
People in the Life Sciences Industry. The honor, announced in the
July/August 2015 issue of PharmaVOICE magazine, recognizes Dr.
Siu’s leadership in developing PAREXEL’s employees and in helping
train the next generation of clinical researchers for the
industry.
At PAREXEL, Dr. Siu leads professional development, management
and leadership, and functional training for more than 18,000 global
employees. From traditional instructor-led settings to eLearning
environments, Siu’s team at PAREXEL provides best-in-class learning
products and customized training programs to present employees with
valuable career and job skills development.
Siu also oversees the global PAREXEL Academy, an externally
focused clinical and regulatory training organization and degree
granting institution with programs tailored to enable clinical
research management practices for learners inside and outside of
PAREXEL.
“Our commitment to our clients starts with a well-trained
workforce. Every day, Albert Siu brings his innovative thinking to
PAREXEL and the PAREXEL Academy, representing and ensuring this
commitment. In the highly complex and regulated drug development
environment, having expertly trained employees around the globe is
essential to help our clients simplify their drug development
journey,” said Josef von Rickenbach, Chairman and CEO, PAREXEL.
The annual PharmaVOICE 100 list honors leaders in the life
sciences who positively impact their peers, their colleagues, their
companies, their communities, as well as the industry at large
through their actions. To read the 2015 PharmaVOICE profiles, visit
www.pharmavoice.com.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51 countries
around the world, and had approximately 18,660 employees in the
fourth quarter. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the
words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. The
Company’s actual future results may differ materially from the
results discussed in the forward-looking statements contained in
this release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from restructurings, including expense
savings from the $30 – $45 million restructuring charge disclosed
in the press release dated June 23, 2015; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company’s recognition of revenue included in backlog;
the Company’s dependence on certain industries and clients; the
Company’s ability to win new business, manage growth and costs, and
attract and retain employees; the Company’s ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company’s business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are discussed
more fully in the section entitled “Risk Factors” of the Company’s
Annual Report on Form 10-K for the fiscal year ended June 30, 2015
as filed with the Securities and Exchange Commission on August 25,
2015, which “Risk Factors” discussion is incorporated by reference
in this press release. The Company specifically disclaims any
obligation to update these forward-looking statements in the
future. These forward-looking statements should not be relied upon
as representing the Company’s estimates or views as of any date
subsequent to the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150923005086/en/
PAREXEL InternationalDiana Martin, +1
781-434-5516Diana.Martin@PAREXEL.comorCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024